MDRA yields 9732.36% · JNJ yields 2.13%● Live data
📍 MDRA pulled ahead of the other in Year 1
Combined, MDRA + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of MDRA + JNJ for your $10,000?
Medra Corporation engages in the acquisition, development, and commercial exploitation of hydrogen-based technologies. The company primarily concentrates on fuel cells, hydrogen-specific sensors, and hydrogen safety. It seeks out technologies, secures those technologies through licensing agreements with the patent holders, and converts the technologies into viable products that it then produces and sells. DCH manufactures and sells a line of hydrogen sensors that are both mobile (a hand held unit) and stationary (wall ceiling or conduit mounted units) to a range of industries and customers. The company also develops, manufactures, and sells fuel cells that range from 12 watts to five kilo watts. Its H2SCAN hydrogen-specific sensing systems offer an alternative to gas detectors used in various industries, including food processing, petrochemical production, semiconductor manufacturing, and glass and metals processing. The company has licenses to various technologies, including The Robust Hydrogen Sensor, The Thick Film Hydrogen Sensor, and The Proton Exchange Membrane Fuel Cell. Medra Corporation was founded in 1994 and is based in Valencia, California.
Full MDRA Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.